Prognostic value of C-reactive protein for heart disease in dialysis patients

Current Opinion in Investigational Drugs

Volumn 6, Issue 9, 2005, Pages 879-886

  Wang, Angela Y M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

C reactive protein; Cardiovascular; Dialysis; Mortality

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN A;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CALCIFICATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS MEMBRANE; DISEASE COURSE; GRAFT INFECTION; HEART DISEASE; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALNUTRITION; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCINOSIS; CARDIOVASCULAR DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS;

EID: 24644434976     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Meyer KB, Levey AS: Controlling the epidemic of cardiovascular disease in chronic renal disease: Report from the National Kidney Foundation Task Force on cardiovascular disease. J Am Soc Nephrol (1998) 9(12 Suppl):S31-S42.
2. Thompson D, Pepys MB, Wood SP: The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure Fold Des (1999) 7(2):169-77.
3. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med (1999) 340(6):448-454.
4. Gershov D, Kim S, Brot N, Elkon KB: C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: Implications for systemic autoimmunity. J Exp Med (2000) 192(9):1353-1363.
5. Chang MK, Binder CJ, Torzewski M, Witztum JL: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA (2002) 99(20):13043-13048.
6. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int (2001) 59(2):407-414.
7. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int (1999) 55(5):1899-1911.
8. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, Paroni R, Malatino LS: Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens (2000) 18(9):1207-1213.
9. Kim SB, Min WK, Lee SK, Park JS, Hong CD, Yang WS: Persistent elevation of C-reactive protein and ischemic heart disease in patients with continuous ambulatory peritoneal dialysis. Am J Kidney Dis (2002) 39(2):342-346.
10. Wang AY, Woo J, Wang M, Sea MM, Ip R, Li PK, Lui SF, Sanderson JE: Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol (2001) 12(9):1927-1936.
11. Ishimura E, Okuno S, Kitatani K, Maekawa K, Izumotani T, Yamakawa T, Jono S, Shoji T, Shioi A, Inaba M, Massry SG, Nishizawa Y. C-reactive protein is a significant predictor of vascular calcification of both aorta and hand arteries. Semin Nephrol (2004) 24(5):408-412.
12. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson JE: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol (2004) 15(8):2186-2194.
13. Park CW, Shin YS, Kim CM, Lee SY, Yu SE, Kim SY, Choi EJ, Chang YS, Bang BK: Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis (2002) 40(6):1230-1239.
14. van Tellingen A, Grooteman MP, Schoorl M, Bartels PC, Schoorl M, van der Ploeg T, ter Wee PM, Nube MJ: Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int (2002) 62(2):632-638.
15. Fine A: Relevance of C-reactive protein levels in peritoneal dialysis patients. Kidney Int (2002) 61(2):615-620.
16. Bergstrom J, Heimburger O, Lindholm B, Qureshi AR: Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. J Am Soc Nephrol (1995) 6(Suppl 1):573.
17. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int (1999) 55(2):1956-1960.
18. Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl (2002) 80:99-102.
19. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int (1999) 55(5):1945-1951.
20. Bellomo G, Lippi G, Saronio P, Reboldi G, Verdura C, Timio F, Timio M: Inflammation, infection and cardiovascular events in chronic hemodialysis patients: A prospective study. J Nephrol (2003) 16(2):245-251.
21. Owen WF, Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int (1998) 54(2):627-636.
22. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M, Koch KM: Chronic Induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int (1996) 16(2):158-162.
23. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS: Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int (1998) 18(4):387-394.
24. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, Sturtevant JM, Isbel NM, Nicol DL, Johnson DW: Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol (2001) 12(4):814-821.
25. Iseki K, Tozawa M, Yoshi S, Fukiyama K: Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant (1999) 14(8):1956-1960.
26. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM: C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int (2002) 62(4):1417-1422.
27. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, Li PK, Sanderson J: Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol (2003) 14(7):1871-1879.
28. Vigil A: Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant (2002) 17(6):1105-1109.
29. Ortega O, Rodriguez I, Carreño GA, Ortiz M, Espejo B, Jimenez J, Gutierrez M, Oliet A, Menon V, Wang X, Greene T et al: Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis (2003) 42(1):44-52.
30. Ducloux D, Kazory A, Chalopin JM: Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int (2004) 66(1):441-447.
31. Winkelmayer WC, Lorenz M, Kramar R, Födinger M, Hörl WH, Sunder-Plassmann G: C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant (2004) 4(7):1148-1154.
32. Varagunam M, Finney H, Trevitt R, Sharples E, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM: Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis (2004) 43(3):502-507.
33. Busch M, Franke S, Müller A, Wolf M, Gerth J, Ott U, Niwa T, Stein G: Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int (2004) 66(1):338-347.
34. López-Gómez JM, Pérez-Flores I, Jofré R, Carretero D, Rodríguez-Benitez P, Villaverde M, Pérez-García R, Nassar GM, Niembro E, Ayus JC: Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol (2004) 15(9):2494-24501.
35. Böger CA, Götz A, Stubanus M, Banas B, Deinzer M, Krüger B, Holmer SR, Schmitz G, Riegger GAJ, Krämer BK: C-reactive protein as predictor of death in end-stage diabetic nephropathy: Role of peripheral arterial disease. Kidney Int (2005) 68(1):217-227.
36. Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT, NECOSAD study group: Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol (2004) 15(11):2916-2922.
37. Nascimento MM, Pecoits-Filho R, Qureshi AR, Hayashi SY, Manfro RC, Pachaly MA, Renner L, Stenvinkel P, Lindholm B, Riella MC: The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: A prospective study. Nephrol Dial Transplant (2004) 19(11):2803-2809.
38. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation (2000) 102(18):2165-2168.
39. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation (2002) 106(12):1439-1441.
40. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation (2003) 107(13):1783-1790.
41. Han KH, Hong KH, Park JH, Ko J, Kang DH, Choi KJ, Hong MK, Park SW, Park SJ: C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation (2004) 109(21):2566-2571.
42. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE: CRP-mediated activation of complement in vivo: Assessment by measuring circulating complement-C-reactive protein complexes. J Immunol (1996) 157(1):473-479.
43. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 190(12):1733-1740.
44. Bhakdi S, Torzewski M, Klouche M, Hemmes M: Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol (1999) 19(10):2348-2354.
45. Zwaka TP, Hombach V, Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation (2001) 103(9):1194-1197.
46. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation (2004) 109(17):2058-2067.
47. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 106(8):913-919.
48. Demer LL, Tintut Y, Parhami F: Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens (2002) 11(4):437-443.
49. Wang AY, Ho SS, Wang M, Liu EK, Ho S, Li PK, Lui SF, Sanderson JE: Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease. Arch Intern Med (2005) 165(3):327-332.
50. Ikeda U, Maeda Y, Yamamoto K, Shimada K: C-reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovasc Res (2002) 56(1):86-92.
51. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD: Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet (1999) 353(9167):1838-1842.
52. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 323(4):236-241.
53. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK: Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int (2003) 63(1):179-185.
54. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Saarsat V, Drueke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant (2001) 16(2):335-340.
55. Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Oritiz M, Tagle R, Gonzalez F, Quiroga T, Caceres MS, Leighton F, Pereira J: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int (2001) 60(5):1844-1850.
56. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol (1998) 9(6):1018-1022.
57. Amann K, Tornig J, Buzello M, Kuhlmann A, Gross ML, Adamczak M, Buzello M, Ritz E: Effect of antioxidant therapy with dl-α-tocopherol on cardiovascular structure in experimental renal failure. Kidney Int (2002) 62(3):877-884.
58. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet (2001) 358(9299):2113-2117.
59. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R, CREED Investigators: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int (2002) 62(1):339-345.
60. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R, CREED Investigators: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol (2002) 13(2):490-496.
61. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G: Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant (2004) 19(6):1507-1519.
62. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini S, Perez-Garcia R, Rindi P, Palla R, Tetta C: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant (2004) 19(5):1154-1160.
63. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules and all-cause mortality and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol (2005) 16(Suppl 1):S83-S88.
64. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis (2000) 35(3):469-476.
65. Haubitz M, Brunkhorst R: C-reactive protein and chronic Chlamydia pneumoniae infection - long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. Nephrol Dial Transplant (2001) 16(4):809-815.
66. Fein PA, Mittman N, Gadh R, Chattopadhay J, Blaustein D, Mushnick R, Avram MM: Malnutrition and inflammation in peritoneal dialysis. Kidney Int Suppl (2003) 87(4):S87-S91.